Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

BICO, Audiocast with teleconference, Q1'24

By Inderes5/7/2024, 8:00 AM
BICO Group

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Maria Forss
00:00 - 03:40

Hello and a warm welcome to everyone for joining BICO AB's earnings call for quarter one 2024. My name is Maria Forss and I'm the CEO and president of BICO AB. And together with our CFO, Jacob Thordenberg, I will present our report for the first quarter of 2024. Let's review today's agenda. Our agenda is divided into five sections before the Q&A section. We will give you a summary of the quarter, highlight significant events from the past quarter, and brief you on the communication yesterday about the change in the method for the impairment test of goodwill, resulting in retroactive impairment of goodwill and other intangible assets. We'll give a brief comment on the market development and outlook, and thereafter present our financial performance for the quarter, as well as how our business areas performed during quarter one. This section will be in listening-only mode. After the presentation, we will move to the Q&A where you can participate and ask questions. The operator will be back with further instructions. This section will be a little more extended for this quarter. And if we take a brief overview of the quarter, it's pleasing to see that we improved our organic growth. However, the mixed performance impacted our profitability. We continue to see slower sales in both academia and diagnostics, and this hampered both sales levels as well as profitability. Our group will comment more on the numbers in the financial section, so I will just conclude on a high level. I will brief you on the strategic review of our current R&D projects and the group product portfolio. This is work that we carry out in preparation for the launch of our updated strategy later this year. I will also brief you on the whistleblower investigation, which we communicated back in March. Our group will inform you about the discussions with the Council for Swedish Financial Reporting Supervision and the retroactive impairment of goodwill and other intangible assets announced yesterday evening. But before that, I would like to spend a minute on presenting our latest additions to the executive management, Katharina Nordland and Anders. We welcomed Katharina in April and Anders will join us mid-June. So yes, those events took place after quarter one, but I think it's worth mentioning during this call, Katharina, our new Chief Human Resources Officer, and her focus will be to enable, shape, and execute BICO AB's global HR strategy to build a people-focused and high-performance culture. And as for Anders, our new Chief Commercial Officer, his main responsibilities will be to scale the BICO business, increasing the commercialization efforts of the portfolio and further exploring opportunities for collaborations and partnerships. They are both great additions to our management team and important cornerstones. When we are reinforcing both investment in people and culture and our increased commercial focus. The conclusions from the whistleblower investigation conducted by an external party at the request of the board of directors were communicated in March. Three aspects should be underlined. First, the whistleblower report refers to historical events from 2017 to 2021. Secondly, the report has not been able to show any criminal act. And third and last, it doesn't lead to any further accounting measures. They work with strengthening. Our internal control systems have been in place since 2022, and we will continue to make sure that we stay proactive, as well as fostering and developing the right business culture. I will now hand over to Jacob for a summary about the impairment of goodwill and other intangible assets.

Jacob Thordenberg
03:41 - 08:00

Thank you, Bruno. Uh, this information was released yesterday evening, Central European Time. Since we resolved on a change of method for impairment tests of goodwill resulting in retroactive impairment of goodwill and other intangible assets for 2022 and 2023. It is important to mention that these adjustments are all non-cash flow items and will not impact Q1 2024 figures negatively. The impairment follows discussions with the Council for Swedish Financial Reporting Supervision regarding impairment tests of goodwill made by BICO AB in 2022 and 2023. The council has, as part of the normal oversight of listed companies, reviewed BICO AB's annual report for 2022 and more precisely, the impairment tests of goodwill, according to IAS 36. We have had a good and constructive dialogue with the Council, where they have advocated that BICO AB should use a five-year forecast period instead of a ten-year model as the ten-year model. According to IAS 36, a ten-year forecast period can only be motivated if underpinned with high forecasting accuracy beyond year five. As disclosed in our annual reports, BICO AB has historically, in its impairment tests, applied a forecast period of ten years. This chosen period of ten years, which has been audited and accepted in our annual reports for 2022 and 2023, was used to reflect what BICO AB believes to be the right value of the businesses, given its growth prospects. It should be noted that BICO AB made changes to the length of the period used in impairment tests as instructed by the Council, from ten to five years. All other parameters such as projections and discount rates have remained unchanged. I will now brief you on the retroactive financial effects on the balance sheet and the profit and loss statements. If we begin with the P&L. When applying the five-year forecast period, it has the following EBIT effect. For 2022, it will be -2,574,000,000, and then a positive effect of 785,000,000 in 2023. The reason for this is that the new forecast period of five years results in a larger historical impairment in 2022 and less impairment in 2023, as previous goodwill impairments made in 2023 were shifted to 2022. And if we go to the next slide and look at the balance sheet. Uh, this is a rather busy slide, but here you see previously reported adjustments and adjusted reported per year end 2022 and 2023 for intangible assets, including goodwill. We have the following: Retroactive change decreased intangible assets with -2,668,000,000 as per year end 2022 compared to the previously reported balance. The corresponding effect as per year end 2023 was -1,838,000,000. Second highlighted item total equity, where the retroactive change has decreased equity with 2,663,000,000 as per year end 2022 compared to the previously reported balance. The corresponding effect as per year end 2023 was -1,808,000,000, and the final box deferred tax liabilities decreased by -5 million as per year end 2022 compared to the previously reported balance. The corresponding effect, as for year end 2023 was -30 million. In total, the goodwill value per year end 2023 has decreased by 1,736,000,000. Detailed information can also be found in note ten in our Q1 report. Back to you, Maria.

Maria Forss
08:02 - 09:04

Thank you. As previously communicated, the review consists of an assessment of the current R&D projects and the group's product portfolio. This work is carried out in preparation before launching the updated strategy. The Project Management Office in BICO is working with the review of R&D projects across the group, and an R&D board has also been established where key projects will be reviewed by executive management, ensuring focused and customer insight-driven R&D investments. Due to the heavy dependency on academia and the diagnostic sectors where the business has been soft for some time, there are certain measures being made in our operating companies selling in cyan. For selling. A new management is in place and measures have been concluded in two specific areas: the commercial offering and cost savings. The commercial offering will be focusing on the core portfolio, and a new strategy has also been implemented to ensure profitable growth. In terms of cost savings, we target savings of 20 million.

Unknown 1
09:05 - 09:06

For.

Maria Forss
09:06 - 10:32

Quarter one has concluded that there was a need for writedowns of capitalized R&D and selling of 85 million, which impacted EBIT for sale. And we are continuing to actively work with restructuring and reshaping of the business, both from an offering and cost perspective. A new commercial lead is in place and in terms of cost savings, we are targeting €1.5 million. This was the last slide of the summary of quarter one, so I will move into the next section and comment on market development and outlook. This is a new section where I will give some more flavor on the market development and outlook, as well as commenting on sales per geography. I believe that we see the same trends and patterns as our peers have reported in quarter one. The indications are that the slower businesses in academia and diagnostic segments continued during quarter one this year. We also saw geographical differences in demand, where sales in North America and Europe are beginning to show positive signs, whereas Asia remains softer. As you can see, our sales were strong in North America and this can mainly be explained by strong sales from biosciences. Europe is performing within the same range as the corresponding quarter last year, as well as the rest of the world. We do see, though, that Asia performed weakly in quarter one, and this was primarily attributable to selling in cyan. I will now hand over to Jacob again for a summary of our financial performance.

Jacob Thordenberg
10:34 - 16:55

Thank you, Brian. I will now summarize the first quarter of 2024. All numbers presented are in Swedish crowns except when otherwise stated. Furthermore, this is also the first quarter where BICO reports in functional reporting and all organic growth figures are in constant currency. BICO delivered sales of 510 million with an organic growth of 5% in the quarter. Adjusted EBITDA amounted to -9 million and EBITDA was -19 million, impacted by the software business in bioprinting and by automation. As previously communicated, this is the first quarter whereby BICO applied functional reporting and comparable numbers have been adjusted. The reason for this is to increase comparability in the company's cost structure and adapt to the most common market practice. The change has affected the reported gross margin negatively as more costs than before, For example, production cost, depreciation on production equipment, etc., have been included in reported cost of goods sold instead of OpEx. The gross margin for the quarter amounted to 45%, which was seven percentage points lower than the corresponding quarter last year. This is explained by the product mix with more revenue from CELLINK with a different gross margin profile compared to our instrument companies, which included more costs in COGS due to its project business, as well as lower sales in bioprinting and bioscience, resulting in less economies of scale on production staff, etc. The net loss for the quarter amounted to -29 million, and if we delve into our net sales for the first quarter, the sales amounted to 510 million, as mentioned, with a total sales growth of 4%. Our business areas delivered mixed sales performance where Biosciences delivered robust sales levels. Historically, Q1 is normally a seasonally weak quarter, and this was no exception for the bioprinting and bioautomation businesses with breakthrough developments in selling and science. It was, however, pleasing to see strong sales levels in bioscience. The indication of slower business in the academia and diagnostic segment continued during Q1 2024. We also saw geographical differences in demand, where sales in North America and Europe began to show positive signs, whereas Asia remains softer; moving on to profitability. Adjusted EBITDA for Q1 amounted to -9 million, corresponding to a margin of -2%. Softer business in bioprinting and bioautomation, primarily in selling and science had a negative impact, which was offset by the strong sales in bioscience. Staying on course with cost control for the group has been guiding for the quarter and will continue to be a focus during the quarters to come. And if we move on to cash flow, cash flow from operating activities for the quarter amounted to -17 million, impacted by the financial performance in the quarter. This also includes a positive effect from changes in working capital of 27 million. Out of this, decrease in operating receivables amounted to 163 million. This is primarily related to accounts receivable being collected in Q1, following our seasonally high sales in Q4. Inventories decreased by 22 million, continuing the trend of decreasing inventory levels as also seen in Q4 2023. Cash flow from changes in operating liabilities amounted to -158 million, primarily related to supplier payments connected to sales in Q4 2023 and contract liabilities converted to revenues. Investments in intangible CapEx amounted to $8 million, and several R&D projects were completed in the second half of 2023, resulting in a reduction in capitalized R&D. Investments in tangible CapEx also amounted to 8 million. Earnout payments amounted to $28 million in the quarter, and the total estimated remaining earnout payments amount to $20 million. Total cash flow during Q1 amounted to -77 million, and cash reserves by the end of March 2024 amounted to 796 million. On this slide, I will further elaborate on working capital improvements during the last quarters. Please note that all working capital numbers are excluding. Between Q1 2023 and Q1 2024. Net working capital decreased from 608 million to 463 million. The main drivers for this development include accounts receivable improvements, which decreased from 442 million to 362 million, an improvement by 80 million, explained by more robust processes including better collection and payment processes, as well as group guidance. Inventories decreased from 506 million to 414 million, an improvement of 92 million. More stringent processes and agreements in place have managed to stop further increases in 2023, and we expect to continue seeing decreasing effects throughout 2024. Working capital liabilities increased modestly by 26 million. Total improvements amounted to 145 million, or a decrease from around 33 to 21% of net working capital in relation to the last 12 months' sales. Maria will now comment on our business areas' performance.

Maria Forss
16:56 - 19:06

Yes, I will guide you through our business areas for the first quarter. The bioprinting business area reported net sales of 113 million in the first quarter. The organic growth in the segment was -21% and the adjusted EBITDA was -21 million, corresponding to a margin of -19%. The business area reported significantly weaker sales compared to the corresponding quarter last year, and the lower sales levels can be explained by a softer market as well as redundant sales efforts. Measures have been concluded in two specific areas: commercial offering and cost savings, as mentioned earlier in this call. Moving on to our next business area, Biosciences. In the first quarter, the business areas. Net sales amounted to 313 million. The organic growth was 36% and the adjusted EBITDA was 35 million, corresponding to a margin of 11%. Biosciences delivered strong sales levels compared with the corresponding quarter last year, and was also affected by the project effect on the business. The significantly stronger sales, as well as continuous cost control, contribute to the positive development in EBITDA margins. Our third business area, Automation, reported in the first quarter net sales of 84 million. The organic growth for the quarter was -27% and adjusted EBITDA amounted to 6 million, corresponding to a margin of 7%. The business area's sales growth was negative compared to the corresponding quarter last year, with sales levels still hampered by weak demand from the diagnostic industry. The profitability for the quarter was negatively impacted by ongoing restructuring, and we're continuing to actively work on reshaping the business, both from an offering and a cost perspective. The Finnish group company Generalist was divested in November 2023 and has been treated as discontinued operations from Q4 2023. With that being said, it's time to open up for our Q&A. Please follow the instructions from the financial hearing host.

Operator
19:10 - 19:35

If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Rickard Krantz from Handelsbanken. Please go ahead.

Unknown 2
19:39 - 20:14

Good morning, and thank you for taking my questions. So, I have a few questions. So first, could you elaborate a bit on the weaker gross margin; perhaps you could provide more commentary in detail around the gross margin contribution, how we should think about that for the BioConvergence business, which seems to be pushing down the gross margin, and should we then expect similar gross margin levels in quarters to come, given the quite significant decline year over year? I guess that would be helpful to understand the trajectory of the gross margin for the full year. Thank you.

Jacob Thordenberg
20:14 - 20:18

Sure. Good question. Yes, as we.

Unknown 1
20:18 - 20:19

Said, the.

Jacob Thordenberg
20:19 - 20:55

Gross margin decreased by seven percentage units quarter over quarter. And this was primarily explained by Sheridan. And the reason for this is that BioSphere has a different gross margin profile than our other instrument companies. And that is that it's a project business. In a project business, you allocate more costs to specific projects. But the consequence of that is that you have less OpEx. So you have an even more fully loaded COGS in a project-based business such as BioSphere. So, going forward,

Unknown 1
20:56 - 20:56

Um.

Jacob Thordenberg
20:56 - 21:10

Any dilution of our margin, you could expect a dilution from our margin if you expect BioSphere to continue to grow. And we do see strong underlying growth in terms of lab automation.

Unknown 2
21:13 - 21:36

All right. Thank you. And I noticed also that consumable sales were down year over year. Um, could you elaborate why that is? And if we should anticipate similar softness in the consumables development and maybe if you could square that also with the sort of installed base and how that's been growing. Thank you.

Unknown 1
21:36 - 21:38

Um, yes.

Jacob Thordenberg
21:38 - 21:52

The decline that we're seeing in consumables is related to what Maria and I commented on, related to SCIENION and CELLINK, which had weaker sales in Q1, and that also includes sales of consumables.

Unknown 2
21:57 - 22:06

All right. Uh, but how should we think about the other business areas in terms of consumable pull through and the momentum there?

Jacob Thordenberg
22:08 - 22:31

I think the way you should see it, we had this question also in the last quarter call, and that is that we have indeed also identified that our levels of consumables and services are too low. And this is a gap that we will address during 2024 to increase the consumable growth, but to answer your question about the decline in Q1, it's related to SCIENION and CELLINK.

Unknown 2
22:33 - 22:49

Claire, um, could you quantify the percentage contribution of sales roughly for CELLINK and SCIENION, respectively? And when should we expect them to achieve sustainable profitability? I'm trying to figure out, you know, how far you have come in the restructuring and the changes you are making there. Thank you.

Unknown 1
22:50 - 22:50

Um.

Jacob Thordenberg
22:51 - 23:34

In terms of weights. I don't want to go into specific weights of these individual companies, but clearly, they are substantial weights within the group. Um, and we are actively doing cost cuts and also actively strengthening the commercial organizations in both CELLINK and SCIENION. When it comes to Sonic, we have a new CEO in place since, uh, roughly a quarter. And then secondly, we have also recruited our new chief commercial officer. I won't be able to give you any guidance on when we can sort of expect to see improvements. But we are working hard on all aspects, both costs and top line in both companies.

Unknown 2
23:36 - 23:42

Okay, but €1.5 million is the target cost saving. Um, sort of a timeline on that one.

Jacob Thordenberg
23:43 - 23:46

It will be implemented during Q1 and Q2.

Unknown 1
23:47 - 23:49

So it has gradually.

Jacob Thordenberg
23:49 - 23:53

Been implemented in Q1, and it will also be implemented partially in Q2.

Unknown 2
23:55 - 24:17

Okay, good. And a final question from my end. Um, so, you know, I think given the extent of the whistleblower announcement in March and the review by the Council for Swedish Financial Reporting Supervision, I am wondering if there are any other active and ongoing investigations into BICO or potential for additional impairments or similar charges. I just wanted to get that out of the way and get a comment on that. Thank you.

Jacob Thordenberg
24:18 - 24:20

There are no other investigations.

Unknown 2
24:22 - 24:23

Thank you for taking my questions.

Unknown 1
24:23 - 24:24

Thank you.

Operator
24:28 - 24:33

The next question comes from Ulrich Ratner from Carnegie. Please go ahead.

Unknown 1
24:36 - 24:37

Thank you very much and good morning.

Unknown 3
24:37 - 25:19

A few questions on my end, and perhaps I'll start off where we left off. And on the goodwill impairment here for Q1. And sure, this is purely mechanical. You're going from ten years to five years in your estimation of goodwill. How should we view this in terms of risk going forward of additional goodwill writedowns? This although it's not a decision on your end and you haven't changed the valuation of each of the individual acquisitions. But is this to be considered more of a conservative view versus previous, you know, the goodwill that.

Unknown 1
25:20 - 25:20

Surrounds the.

Jacob Thordenberg
25:20 - 25:44

Short sale? Yes. Now it's a much more conservative view because what happens is you basically cut the forecast from 10 to 5 years. So instead of calculating a terminal value after ten years, you calculate it after five years. Where we believe that the companies have not reached a steady state in terms of sales and profitability. So this is indeed a much more conservative approach.

Unknown 1
25:45 - 25:46

Okay, great.

Unknown 3
25:47 - 26:15

Um, and again, going back to a previous question here, you mentioned gross margin potentially declining with zero acceleration due to the service business. But since this is a bit of a special segment in terms of its reporting and dynamic between gross margin and EBITDA margin, could you give us some guidance on how acceleration in biosphere will affect the EBITDA margin for the bioscience segment?

Jacob Thordenberg
26:19 - 26:46

I mean, that would be giving guidance on biosphere. And as I said to Richard, we do see a strong underlying demand for lab automation. So we expect to see nice, healthy growth in biosphere during 2024. With this, you will see a diluted effect on our gross margin. Uh, given the explanation I gave to Rika, uh, that is related to biosphere having a different gross margin profile than the other companies.

Unknown 3
26:47 - 27:00

Okay, let me then sort of rephrase it. Um, is biosphere and this is essentially not guidance but is biosphere reporting higher EBITDA margin versus the overall group.

Unknown 1
27:01 - 27:01

Yes.

Unknown 3
27:03 - 27:08

Okay. So essentially it will be margin accretive not be decritive if it accelerates.

Unknown 1
27:08 - 27:09

Yeah.

Jacob Thordenberg
27:09 - 27:09

Yes, yes.

Unknown 3
27:11 - 27:13

Great. Um, third question I think.

Unknown 1
27:13 - 27:14

That I think that's important.

Jacob Thordenberg
27:14 - 27:18

I think that's important to understand that the gross margin profile in biosphere.

Unknown 1
27:18 - 27:19

Zero.

Jacob Thordenberg
27:19 - 27:27

Is that it's much more fully loaded than the instrument companies, and that means that the level of opex in biosphere is much less.

Unknown 1
27:27 - 27:28

Yes. Yeah.

Unknown 3
27:28 - 27:54

That was more or less my point. Um, and on bioprinting, um, it seems to be a bit of a struggle here for Q4 and for Q1. And how much would you attribute this to the underlying market, especially given that you're taking some cost savings related to this segment and streamlining of product offerings?

Maria Forss
27:56 - 28:52

When it comes to the market. It's especially the Asian market that is affecting the sales negatively for CELLINK as well as the heavy dependence on the academic sector. And, um, the measures that we're taking for CELLINK are two-fold; one, it's ensuring that we have a focused product offering, ensuring that we're selling profitable products. And secondly, Jacob also referred to doing cost savings, and for CELLINK, it's in the range of $20 million now for the next quarter. So it's a mix of underlying market conditions where academia is still softer, and Asia is also still soft. Um, and um, the product offer. So it's a mixture of hope that answers your question.

Unknown 3
28:53 - 29:18

Yes, absolutely. Automation and diagnostics have been weak markets for some time, but we're hearing from industry peers that the outlook is a bit brighter for the second half of the year. Can you give us any rough indication of current trading or when this negative trend might change?

Jacob Thordenberg
29:21 - 29:28

I think it's difficult to give indications on when we will see a stop to the negative trend. Um.

Unknown 1
29:31 - 29:32

We do see.

Jacob Thordenberg
29:32 - 29:33

That the market is.

Unknown 1
29:33 - 29:34

Picking up for our peers.

Jacob Thordenberg
29:34 - 29:52

So that's a positive sign. What we are mainly focusing on at Siemian is making cost cuts to right-size the business. In addition to that, we're also significantly strengthening the commercial team.

Unknown 3
29:55 - 30:51

Okay, last question on my end. Um, I know that you're currently in a strategic review, and I'm guessing you would like to reveal the highlights of this at the Capital Markets Day. I did note that you were planning something for September. Uh, just broad-based here. Um, you have invested a lot in R&D over the years. Um, do you feel that this level of investment needs to be maintained and just allocated differently, or is there a case here where you can reduce R&D based on your current product offerings, as well as within this strategic review? Does it only include keeping or focusing on your current portfolio, or also potentially divesting certain parts of your portfolio, which might not be a good strategic fit for Miko?

Maria Forss
30:53 - 32:13

Mr., the strategic review is done. Uh, both, uh, in terms of the current portfolio, ensuring that the needs of our customers are addressed in the best way. And in terms of the gaps that potentially exist within the current portfolio in relation to market trends and competition, we will have to complement those gaps with either collaborations, agreements with different companies, or by developing new R&D projects. And the second part of reviewing our R&D pipeline is not only to ensure that we deploy our R&D investments in the right fields, but also to ensure a focused portfolio, whether we are to, uh, and I would presume that the review we are conducting now means that we will close some projects, but that doesn’t necessarily mean that we will invest less money, but rather invest properly in more focused and fewer projects and ensure that they are successful in terms of divesting any assets. Uh, no such decisions have been made.

Unknown 1
32:15 - 32:16

Okay, great.

Unknown 3
32:16 - 32:35

Just a follow-up question. Jacob, you mentioned that additional investments have been made in Siemian to expand its commercial capacities. Just some clarification. Is that related to bioconvergence or is that related to Siemian, or both?

Unknown 1
32:36 - 32:36

Okay.

Unknown 3
32:38 - 32:38

Great.

Maria Forss
32:38 - 33:10

Um, I think overall, um, as part of the commercial excellence and driving that, that includes measures that are being done in science at SCENION with the new, uh, commercial lead. Uh, we have a new, uh, CEO also commercially driven in selling, but it's the same kind of, uh, uh, initiatives that are taking place throughout the group to ensure that we leverage our commercial abilities to a larger extent than previously made.

Unknown 1
33:12 - 33:12

It's great.

Unknown 3
33:13 - 33:27

And if I can just squeeze in one last question, and I know you talk about a struggling Asian market. Have you seen any positive effects from the Sartorius commercial collaboration?

Maria Forss
33:28 - 34:05

When it comes to the Sartorius collaboration that was, uh, set in stone last year. Uh, we have both the commercial collaboration as well as R&D collaboration and mainly the collaboration in terms of their distributing our instruments is in Asia and Asia is being softer. So, yes, there is traction. Uh, not at the speed potentially that, uh, I think both parties would have wanted, but, um, Asia is what it is at the moment. And, uh, I don't see that it's going to remain like that. Uh. Moving on. So we see positive results from that collaboration.

Unknown 3
34:06 - 34:10

Hey. Great. Uh, that was all on my end. Thank you, Maria and Jacob, and I'll get back into the queue.

Unknown 1
34:11 - 34:12

Thank you.

Operator
34:16 - 34:22

The next question comes from Ricard and Kranz from Handelsbanken. Please go ahead.

Unknown 2
34:25 - 34:41

Here, a follow-up on bioconvergence. So at the time of acquisition, CELLINK in 2021 had around, you know, a 25-plus percent EBITDA margin. Is that, uh, level where the company is performing at the moment?

Jacob Thordenberg
34:43 - 34:44

Uh, yes.

Unknown 2
34:46 - 34:48

Perfect. Very helpful. Thanks for taking my question.

Operator
34:55 - 35:15

As a reminder, if you wish to ask a question, please dial Pound Key five on your telephone keypad. There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.

Maria Forss
35:17 - 35:26

Thank you everyone for joining us today. And thank you for all the questions. And together with Jacob, I would like to wish everyone a great Tuesday. Thank you and goodbye.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…